Deakin University
Browse

File(s) under permanent embargo

Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296 (Kidney International (2020) 97(6) (1287–1296), (S0085253820301526), (10.1016/j.kint.2020.01.035))

journal contribution
posted on 2023-02-23, 00:59 authored by E Rondeau, M Scully, G Ariceta, T Barbour, S Cataland, N Heyne, Y Miyakawa, S Ortiz, E Swenson, M Vallee, S S Yoon, D Kavanagh, H Haller, S Babu, N Broeders, N Lietar, F Brown, P Campbell, J M Campistol, M Blasco, P Chowdhury, T Kasimatis, L Cirami, L Caroti, G Antognoli, Y Delmas, V Dobronravov, A Gaeckler, C Garrouste, G Greenwood, S Griffin, C C Huang, I R Chen, S Huang, J S Kim, G La Manna, G Comai, M Cappuccilli, M Le Quintrec, G Jeantet, I Fumie, Y Luque, J Menne, J Morelle, E Goffin, A Muhlfeld, S Nagaraj, G Arepally, D Oh, M Okumi, M P Terente, E Gutierréz, P Rodriguez, F Provot, U Schönermarck, M Fischereder, N R Terrada, B Seitz-Polski, G Favre, S Boyer-Suavet, M Vinogradova, T Kirsanova, E K S Wong
The authors regret that 2 investigators were not included in the 311 Study Group. Members of the 311 Study Group are listed in the Appendix. The authors would like to apologize for any inconvenience caused.

History

Journal

Kidney International

Volume

99

Pagination

1244 - ?

ISSN

0085-2538

eISSN

1523-1755

Usage metrics

    Research Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC